Non-invasive prenatal testing - No risk to mother and baby
Non-invasive prenatal testing (NIPT) is a new method of testing for common chromosomal abnormalities that can occur in a developing baby. While rare, these chromosome abnormalities can have profound consequences to the life and health of you and your child and it is important to find out as soon as possible.
How does NIPT work?
Small amounts of a baby’s DNA passes into the bloodstream of the mother during pregnancy. New technology allows us to analyse this DNA directly from the mother’s blood and screen for chromosomal abnormalities.
Previously, it was only possible to test for these abnormalities with highly invasive procedures that carried a risk to the pregnancy. Chorionic villus sampling (CVS) can be performed between weeks 10-12 and pregnancy, and amniocentesis performed between weeks 15–18 of pregnancy. These tests carry up to 1 in 150 or 1 in 100 chance of miscarriage respectively.
Initial screening with non-invasive prenatal testing can help to avoid this potentially unnecessary and invasive testing. There is no risk to mother or baby and NIPT provides the earliest testing available.
What does CentoNIPT® screen for?
- Down syndrome (Trisomy 21), which is caused by an extra copy of chromosome 21. Mild/moderate mental retardation and risk of some birth defects (affects 1 in 1,000 live births).
- Edwards syndrome (Trisomy 18), which is caused by an extra copy of chromosome 18. Severe mental retardation and risk of multiple birth defects (affects 1 in 3,000-6,000 live births).
- Patau syndrome (Trisomy 13), which is caused by an extra copy of chromosome 13. Severe mental retardation and risk of multiple birth defects (affects 1 in every 5,000 live births).
The test can also detect abnormalities of the sex chromosomes:
- Turner syndrome (Monosomy X), which is caused by a missing X chromosome in females
- Klinefelter syndrome (XXY), which is caused by an extra X chromosome in males
- Jacobs syndrome (XYY), which is caused by an extra Y chromosome in males
- Triple X syndrome (XXX), which is caused by an extra X chromosome in females
How is the test performed?
A simple blood sample is taken by your doctor, using the CentoNIPT® set. The sample is then shipped to CENTOGENE’s laboratory for analysis. Test results are typically returned to your doctor within 5 days of sample receipt.
Why should you choose CentoNIPT®?
- Completely safe for you and your baby
- High level of accuracy
- Test from the 10th week of pregnancy
- Only a single blood sample required
- Results returned within 5 days of sample receipt
What is the workflow of CentoNIPT®?
Your physician will determine if CentoNIPT® is appropriate for you.
For CentoNIPT® just 9ml of maternal blood are needed.
CentoNIPT® is performed under the highest quality standards. The results will be available within 5 working days after sample receipt.
The report is shared exclusively with your physician who will discuss the results with you.
Frequently asked questions
During pregnancy, there are pieces of your baby’s DNA circulating in your own blood. NIPT analyzes these DNA to pinpoint a baby’s risk of having specific genetic disorders, including Down syndrome, Patau syndrome, Edwards syndrome, and several gender chromosomal disorders.
NIPT is non-invasive prenatal test. For this test, only 9 ml blood will be sufficient.
The procedure is completely risk free for mother and baby.
Compared to conventional screening methods like ultrasound or serum screening, the reliability of NIPT is much higher.
NIPT calculates the risk of the defined chromosomal disorders and helps your doctor to estimate these risk. The result is presented as “YES” or “NO”
YES – indicates an extra copy of one chromosome is detected. An invasive prenatal genetic test will be necessary to confirm the genetic diagnosis.
NO – no extra copy of the specific chromosomes. The risk of being affected is low.
NIPT can be performed already after 10 weeks of gestation; whereas chorionic villus sampling is done between 10-12 weeks of gestation; amniocentesis between 14 -16 weeks of gestation.
Yes, reporting the gender is one option in NIPT. In general, the gender information will not be provided before 12 weeks of gestation, as regulated by German law.
Yes, the portion of your twins’ DNA within your maternal blood can be analyzed in the same way as for singleton pregnancies.
Notation: *Sample Preparation and analysis software are CE-IVD marked
Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision.